6 results about "Staphylococcus haemolyticus" patented technology

The invention discloses an application of a small molecule compound DK419 in preparation of a drug for resisting staphylococcus infection, and the CAS number of the small molecule compound DK419 is 2102672-22-8; the staphylococcus comprises at least one of staphylococcus aureus, staphylococcus epidermidis, staphylococcus hominis, staphylococcus capitis and staphylococcus haemolyticus. According to the technical scheme, the novel medical application of DK419 is disclosed, DK419 has the effects of inhibiting growth of staphylococcus and killing staphylococcus aureus, the antibacterial effect is better than that of first-line antibiotic vancomycin, and the bactericidal effect is equal to that of vancomycin; the DK419 has the effect of efficiently removing a biofilm; the DK419 can play a role in resisting staphylococcus aureus infection in an in-vivo skin infection model.

Described herein are compositions, methods, and kits for detecting wound pathogens. One embodiment described herein is primer pairs and probes for individual, simultaneous, or sequential multiplex polymerase chain reaction (PCR) based assays for the detection of Acinetobacter baumannii, Bacteroides fragilis, Clostridium perfringens, Enterobacter cloacae, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Klebsiella pneumoniae, Klebsiella Oxytoca, Klebsiella aerogenes, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Serratia marcescens, Staphylococcus aureus, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus pyogenes, Streptococcus anginosus, Staphylococcus lugdunensis, Providencia stuartii, Stenotrophomonas maltophilia, Morganella morganii, Citrobacter koseri, Citrobacter freundii, Citrobacter braakii, Peptoniphilus asaccharolyticus, Peptoniphilus harei, Peptoniphilus ivorii, Peptostreptococcus anaerobius, Finegoldia magna, Clostridium septicum, Paeniclostridium sordellii (Clostridium sordellii), Clostridium novyi A, B, Clostridium histolyticum, Staphylococcus epidermidis, Staphylococcus haemolyticus, Corynebacterium striatum, Candida albicans, Candida auris, Candida glabrata, Candida krusei, Candida parapsilosis, or Candida tropicalis.

The invention discloses a strain of phyllosphere fungus (Muyocopron lithocarpi) DP16 and application of the strain of Muyocopron lithocarpi) DP16 and application of the strain of Muyocopron lithocarpi. The strain DP16 provided by the invention is preserved in the China Center for Type Culture Collection on June 23, 2025, and the preservation number is CCTCC NO: M 20251445. The DP16 provided by the invention can be used for effectively inhibiting various plant pathogenic fungi and bacteria, and particularly shows strong activity on elaeagnus pungens, staphylococcus haemolyticus, African neem brown root pathogenic bacteria and the like. And the fermentation extract also has obvious oxidation resistance. The invention further provides an optimal fermentation culture method of the strain, an extraction method of secondary metabolites and application of the strain in preparation of biological control preparations and antioxidants, and important microbial resources and technical support are provided for development of novel and safe biopesticides and functional products.

A freeze-dried formulation includes an antibacterial protein having a killing activity specific to at least one or all of the following genera: Staphylococcus arlettae, Staphylococcus aureus, Staphylococcus auricularis, Staphylococcus carnosus, Staphylococcus caprae, Staphylococcus chromogenes, Staphylococcus cohnii, Staphylococcus delphini, Staphylococcus epidermidis, Staphylococcus equorum, Staphylococcus gallinarum, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus intermedius, Staphylococcus kloosii, Staphylococcus lentus, Staphylococcus lugdunensis, Staphylococcus muscae, Staphylococcus pasteuri, Staphylococcus saprophyticus, Staphylococcus warneri, and Staphylococcus xylosus; a poloxamer; a sugar; and an amino acid.

The present technology relates generally to the field of reducing, preventing, or ameliorating the generation of undesirable body odors emanating from the skin. In particular, the present technology discloses ApatB-Staphylococcus haemolyticus bacterial strains, which have been modified to reduce or prevent the production of 3-methyl-3- sulfanylhexan-l-ol (3M3SH), compositions and pharmaceutical comprising one or more of said strains, methods of genetically engineering said strains, methods for reducing body odor using said strains, and methods for altering a microbiome using said strains.

The application discloses a bacillus cereus ATP synthase beta subunit antibacterial peptide BaD9, and the amino acid sequence of the bacillus cereus ATP synthase beta subunit antibacterial peptide BaD9 is KLVVHRARRIQFFLSQNFH, and the molecular weight of the antibacterial peptide is 2396.831 Dalton. The antibacterial peptide has obvious inhibiting effect on Vibrio parahaemolyticus, Staphylococcus aureus and Staphylococcus haemolyticus, and can be used for preparing medicines for preventing or inhibiting Vibrio parahaemolyticus, Staphylococcus aureus and Staphylococcus haemolyticus infection, food preservatives or feed additives.